We are live on
!
Find out more
SC
Stempoint Capital Portfolio holdings
AUM
$522M
1-Year Est. Return
281.95%
This Fund
S&P 500
This Quarter
Est. Return
+12.43%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$334M
AUM Growth
-$6.26M
(-1.8%)
Cap. Flow
-$20.2M
Cap. Flow
% of AUM
-6.04%
Top 10 Holdings %
Top 10 Hldgs %
55.99%
Holding
67
New
24
Increased
10
Reduced
18
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$12.9M |
| 2 |
Incyte
INCY
|
+$8.26M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
+$8.02M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$7.82M |
| 5 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$7.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Crinetics Pharmaceuticals
CRNX
|
+$17.4M |
| 2 |
ACLX
Arcellx
ACLX
|
+$14.7M |
| 3 |
Immunocore
IMCR
|
+$11.5M |
| 4 |
Merck
MRK
|
+$10.2M |
| 5 |
Immunovant
IMVT
|
+$10.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.38% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
CALL
Syndax Pharmaceuticals
SNDX
$2.02B
| $382K | 0.11% |
+230,000
| New | +$4.75M |
|
|
52
CALL
Immunovant
IMVT
$8.27B
| $113K | 0.03% |
+200,000
| New | +$5.9M |
|
|
APLT
53
CALL
DELISTED
Applied Therapeutics
APLT
| $75.5K | 0.02% |
+251,600
| New | +$1.48M |
|
|
54
CALL
Arcutis Biotherapeutics
ARQT
$3.56B
| $12.5K | ﹤0.01% |
250,000
-250,000
| -50% | -$2.47M |
|
55
Black Diamond Therapeutics
BDTX
$103M
| – | – |
-674,198
| Closed | -$3.14M |
|
56
Celldex Therapeutics
CLDX
$2.77B
| – | – |
-144,467
| Closed | -$5.35M |
|
57
Corbus Pharmaceuticals
CRBP
$167M
| – | – |
-101,479
| Closed | -$4.59M |
|
58
Fulcrum Therapeutics
FULC
$243M
| – | – |
-696,464
| Closed | -$4.32M |
|
59
GSK
GSK
$104B
| – | – |
-245,933
| Closed | -$9.47M |
|
|
60
Immunocore
IMCR
$1.78B
| – | – |
-339,351
| Closed | -$11.5M |
|
61
Insmed
INSM
$23.5B
| – | – |
-86,980
| Closed | -$5.83M |
|
62
Jasper Therapeutics
JSPR
$24.8M
| – | – |
-143,775
| Closed | -$3.26M |
|
|
KALV
63
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-736,765
| Closed | -$8.68M |
|
64
Larimar Therapeutics
LRMR
$384M
| – | – |
-704,349
| Closed | -$5.11M |
|
|
65
Merck
MRK
$315B
| – | – |
-81,508
| Closed | -$10.2M |
|
|
SLN
66
Silence Therapeutics
SLN
$496M
| – | – |
-124,866
| Closed | -$2.37M |
|
67
Spyre Therapeutics
SYRE
$8.7B
| – | – |
-150,450
| Closed | -$3.54M |
|
Similar funds
JE
GS
LT
WFA
TCM
SCM
ETS
CM
Stempoint Capital's Q3 2024 Portfolio in Review
As of Q3 2024, Stempoint Capital held 67 positions worth $334M, down 1.8% from $340M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Stempoint Capital withdrew a net $20.2M in Q3 2024, closing 13 positions and reducing 18 holdings. Its most notable exit was Immunocore, an estimated $11.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.
Against the trend, Stempoint Capital opened a new position in Bristol-Myers Squibb worth $14.2M.
- Stempoint Capital's largest Q3 2024 buy was Bristol-Myers Squibb: 275,303 shares worth $14.2M.
- Stempoint Capital added most to Arcutis Biotherapeutics in Q3 2024, an estimated $8.02M increase.
- Stempoint Capital's biggest Q3 2024 reduction was Crinetics Pharmaceuticals, cutting an estimated $17.4M.
- Stempoint Capital fully exited Immunocore in Q3 2024, selling an estimated $11.5M.
- Stempoint Capital's ten largest holdings make up 56% of its $334M portfolio in Q3 2024.
- Stempoint Capital opened 24 new positions and closed 13 in Q3 2024.
- Stempoint Capital's portfolio value fell 1.8% quarter-over-quarter to $334M.
Based on Stempoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.